Peter L. Turecek

5.0k total citations · 1 hit paper
143 papers, 3.7k citations indexed

About

Peter L. Turecek is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, Peter L. Turecek has authored 143 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 31 papers in Immunology and 26 papers in Molecular Biology. Recurrent topics in Peter L. Turecek's work include Platelet Disorders and Treatments (70 papers), Hemophilia Treatment and Research (60 papers) and Blood Coagulation and Thrombosis Mechanisms (39 papers). Peter L. Turecek is often cited by papers focused on Platelet Disorders and Treatments (70 papers), Hemophilia Treatment and Research (60 papers) and Blood Coagulation and Thrombosis Mechanisms (39 papers). Peter L. Turecek collaborates with scholars based in Austria, United States and Germany. Peter L. Turecek's co-authors include Inge A. Ivens, Mary J. Bossard, Freddy Schoetens, Katalin Váradi, Hans Peter Schwarz, Herbert Gritsch, H. P. Schwarz, Hans Peter Schwarz, Friedrich Dorner and Paul Knöbl and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Analytical Chemistry.

In The Last Decade

Peter L. Turecek

132 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs

2016 539 citations Peter L. Turecek, Mary J. Bossard et al. Journal of Pharmaceutical Sciences profile →

Peers

Peter L. Turecek

HEMAT

IMMUN

GENET

RNMI

Olivier D. Christophe France

B Furie United States

Gerrit Jan Schuurhuis Netherlands

Lars C. Petersen Denmark

Graham Molineux United States

George M. Willems Netherlands

Kenneth R. Bridges United States

Barend Bouma Netherlands

William J. Lane United States

Jialan Shi United States

Olivier D. Christophe France

Peter L. Turecek

2.3k ×1.2

HEMAT

1.3k ×1.4

927 ×1.3

IMMUN

612 ×1.2

GENET

349 ×1.0

RNMI

Citations per year, relative to Peter L. Turecek Peter L. Turecek (= 1×) peers Olivier D. Christophe

Countries citing papers authored by Peter L. Turecek

Since Specialization

Citations

This map shows the geographic impact of Peter L. Turecek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter L. Turecek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter L. Turecek more than expected).

Fields of papers citing papers by Peter L. Turecek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter L. Turecek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter L. Turecek. The network helps show where Peter L. Turecek may publish in the future.

Co-authorship network of co-authors of Peter L. Turecek

This figure shows the co-authorship network connecting the top 25 collaborators of Peter L. Turecek. A scholar is included among the top collaborators of Peter L. Turecek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter L. Turecek. Peter L. Turecek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mascher, Daniel, et al.. (2025). Evaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population. International Journal of Toxicology. 44(6). 451–457.

Holle, Lori A., et al.. (2024). Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma. Research and Practice in Thrombosis and Haemostasis. 8(1). 102337–102337.

Holik, Ann‐Katrin, et al.. (2024). An Automated pre-Dilution Setup for Von Willebrand Factor Activity Assays. BIO-PROTOCOL. 14(1352). e5059–e5059. 1 indexed citations

Binder, Nikolaus B., et al.. (2021). Clinical use of thrombin generation assays. Journal of Thrombosis and Haemostasis. 19(12). 2918–2929. 69 indexed citations

Weber, Alfred, et al.. (2019). Polysialic Acid-Mediated Activity Measurement of Polysialylated Recombinant Coagulation Factor VIII. Journal of Pharmaceutical Sciences. 109(2). 966–974. 1 indexed citations

Turecek, Peter L., et al.. (2016). A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 22(6). 957–965. 53 indexed citations

Turecek, Peter L., Mary J. Bossard, Freddy Schoetens, & Inge A. Ivens. (2016). PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. Journal of Pharmaceutical Sciences. 105(2). 460–475. 539 indexed citations breakdown →

Sonneveld, Michelle, Moniek P.M. de Maat, Marileen L.P. Portegies, et al.. (2015). Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 126(25). 2739–2746. 122 indexed citations

Bonazza, Klaus, Hanspeter Rottensteiner, Gerald Schrenk, et al.. (2015). Ca2+ concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy. Analytical and Bioanalytical Chemistry. 407(20). 6051–6056. 9 indexed citations

10.

Skalicky, Susanna, Paul Knöbl, Barbara Plaimauer, et al.. (2014). A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay. Journal of Thrombosis and Haemostasis. 12(9). 1523–1532. 3 indexed citations

11.

Mannucci, Pier Mannuccio, Christine L. Kempton, Carolyn M. Millar, et al.. (2013). Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 122(5). 648–657. 87 indexed citations

12.

Váradi, Katalin, Hanspeter Rottensteiner, Susanne Vejda, et al.. (2009). Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor. Journal of Thrombosis and Haemostasis. 7(7). 1134–1142. 16 indexed citations

13.

Gerenčer, Marijan, Peter L. Turecek, Otfried Kistner, et al.. (2006). In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L.. Antiviral Research. 72(2). 153–156. 33 indexed citations

14.

Váradi, Katalin, Peter L. Turecek, & H. P. Schwarz. (2004). Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia. 10(s2). 17–21. 51 indexed citations

15.

Tripodi, Armando, Veena Chantarangkul, Martina Böhm, et al.. (2004). Measurement of von Willebrand factor cleaving protease (ADAMTS‐13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. Journal of Thrombosis and Haemostasis. 2(9). 1601–1609. 64 indexed citations

16.

Bonderman, Diana, Peter L. Turecek, Johannes Jakowitsch, et al.. (2003). High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis. 90(9). 372–376. 161 indexed citations

17.

Krebs, Michael, Bernhard M. Meyer, Peter Quehenberger, et al.. (2002). Massive postoperative intramuscular bleeding in acquired von Willebrand's disease. Annals of Hematology. 81(7). 394–396. 5 indexed citations

18.

Thomas, K. B., et al.. (1999). Continuous infusion of FVIII and FIX concentrates:in vitroanalysis of clinically relevant parameters. Haemophilia. 5(1). 17–25. 8 indexed citations

19.

Turecek, Peter L., Katalin Váradi, Herbert Gritsch, et al.. (1999). Factor Xa and Prothrombin: Mechanism of Action of FEIBA. Vox Sanguinis. 77(S1). 72–79.

20.

Turecek, Peter L., Engelbert Buxbaum, & Fritz Pittner. (1989). Quantitative determination of pectic substances as an example of a rhamnopolysaccharide assay. Journal of Biochemical and Biophysical Methods. 19(2-3). 215–222. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact